Microsecretory Adenocarcinoma of Salivary Glands: An Expanded Series of 24 Cases.
Actins
/ metabolism
Adenocarcinoma
/ metabolism
Adolescent
Adult
Aged
Aged, 80 and over
Calcium-Binding Proteins
/ metabolism
Female
Humans
Immunohistochemistry
Male
Microfilament Proteins
/ metabolism
Middle Aged
S100 Proteins
/ metabolism
SOXE Transcription Factors
/ metabolism
Salivary Gland Neoplasms
/ metabolism
Transcription Factors
/ metabolism
Tumor Suppressor Proteins
/ metabolism
Young Adult
Calponins
Adenocarcinoma not otherwise specified
MEF2C-SS18
Microsecretory adenocarcinoma
Salivary gland neoplasms
Journal
Head and neck pathology
ISSN: 1936-0568
Titre abrégé: Head Neck Pathol
Pays: United States
ID NLM: 101304010
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
received:
26
04
2021
accepted:
28
04
2021
pubmed:
14
5
2021
medline:
23
3
2022
entrez:
13
5
2021
Statut:
ppublish
Résumé
Microsecretory adenocarcinoma (MSA) is a recently described salivary gland tumor with a characteristic histologic and immunophenotypic profile and recurrent MEF2C-SS18 fusions. Because only six cases of MSA have been published, its complete clinicopathologic spectrum is unclear, and its biologic behavior has not been documented. Here, we present an updated and expanded experience of 24 MSA cases. All cases of MSA were obtained from the authors' files. Immunohistochemistry for S100, SOX10, p63, p40, SMA, calponin, and mammaglobin was performed. Molecular analysis was performed by targeted RNA sequencing, SS18 break apart fluorescence in situ hybridization, and/or reverse transcriptase polymerase chain reaction for MEF2C-SS18 fusion. Clinical follow-up was obtained from medical records. A total of 24 MSA cases were collected, from 13 women and 11 men, ranging from 17 to 83 years (mean 49.5 years). The vast majority (23 of 24) arose in the oral cavity, with the palate (n = 14) and buccal mucosa (n = 6) as the most frequent subsites. Tumors showed consistent histologic features including: (1) microcystic tubules, (2) flattened intercalated duct-like cells, (3) monotonous oval hyperchromatic nuclei, (4) abundant basophilic luminal secretions, (5) fibromyxoid stroma, and (6) circumscribed borders with subtle infiltration. The tumors were very consistently positive for S100 (24 of 24), p63 (24 of 24), and SOX10 (14 of 14) and negative for p40 (0 of 21), calponin (0 of 12) and mammaglobin (0 of 16), while SMA (4 of 20) was variable. MEF2C-SS18 fusion was demonstrated in 21 of 24 cases; in the remaining 3 cases with insufficient RNA, SS18 break apart FISH was positive. Treatment information was available in 17 cases, all of which were managed with surgery only. In 14 cases with follow-up (1-216 months, mean 30), no cases recurred or metastasized. MSA is a distinct salivary gland neoplasm with remarkably consistent clinical, histologic, immunophenotypic, and genetic features that generally behaves in an indolent manner following surgery alone. These observations solidify MSA as a unique, low-grade salivary gland carcinoma that warrants inclusion in the next version of the WHO classification of head and neck tumors.
Identifiants
pubmed: 33982215
doi: 10.1007/s12105-021-01331-7
pii: 10.1007/s12105-021-01331-7
pmc: PMC8633253
doi:
Substances chimiques
Actins
0
Calcium-Binding Proteins
0
Microfilament Proteins
0
S100 Proteins
0
SOX10 protein, human
0
SOXE Transcription Factors
0
TP63 protein, human
0
Transcription Factors
0
Tumor Suppressor Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1192-1201Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Genes Chromosomes Cancer. 2011 Jul;50(7):559-70
pubmed: 21484932
J Oral Maxillofac Surg. 2006 Mar;64(3):415-23
pubmed: 16487803
Head Neck Pathol. 2020 Sep;14(3):630-636
pubmed: 31605313
Am J Surg Pathol. 2018 Feb;42(2):e11-e27
pubmed: 29076877
Am J Surg Pathol. 2021 Oct 1;45(10):1337-1347
pubmed: 33739781
Blood Cancer J. 2015 Jun 19;5:e320
pubmed: 26090620
Head Neck Pathol. 2015 Mar;9(1):79-84
pubmed: 24969705
Clin Cancer Res. 2016 Sep 15;22(18):4623-33
pubmed: 27103403
Head Neck Pathol. 2021 Sep;15(3):723-726
pubmed: 33394377
Am J Surg Pathol. 2004 Jan;28(1):89-93
pubmed: 14707869
Cancer Discov. 2016 Feb;6(2):176-87
pubmed: 26631070
Cancer Prev Res (Phila). 2016 Apr;9(4):265-74
pubmed: 26862087
Genome Biol. 2019 Oct 21;20(1):213
pubmed: 31639029
Am J Surg Pathol. 2021 Jun 1;45(6):753-764
pubmed: 33284193
Pathol Int. 2020 Oct;70(10):781-785
pubmed: 32687666
Clin Cancer Res. 2016 Feb 1;22(3):725-33
pubmed: 26631609
Head Neck Pathol. 2014;8(3):250-60
pubmed: 24446021
Am J Surg Pathol. 2019 Aug;43(8):1023-1032
pubmed: 31094920
Head Neck Pathol. 2020 Dec;14(4):982-990
pubmed: 32436169
Head Neck Pathol. 2013 Jul;7 Suppl 1:S85-9
pubmed: 23821216
Am J Surg Pathol. 2010 May;34(5):599-608
pubmed: 20410810
Oral Oncol. 2007 Jan;43(1):67-76
pubmed: 16807072
Am J Surg Pathol. 2018 Aug;42(8):1076-1082
pubmed: 29738361